OraSure Technologies, Inc. (NASDAQ:OSUR – Get Free Report) was the recipient of a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 1,360,000 shares, a decline of 33.3% from the August 31st total of 2,040,000 shares. Based on an average daily volume of 784,900 shares, the short-interest ratio is presently 1.7 days.
OraSure Technologies Stock Performance
Shares of OSUR opened at $4.21 on Thursday. The company has a 50 day moving average price of $4.32 and a 200-day moving average price of $4.88. OraSure Technologies has a fifty-two week low of $3.91 and a fifty-two week high of $8.45. The stock has a market capitalization of $313.94 million, a PE ratio of 14.03 and a beta of 0.05.
OraSure Technologies (NASDAQ:OSUR – Get Free Report) last posted its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share for the quarter. OraSure Technologies had a return on equity of 9.15% and a net margin of 9.88%. The company had revenue of $54.34 million during the quarter, compared to analyst estimates of $53.35 million. Equities research analysts forecast that OraSure Technologies will post -0.11 EPS for the current year.
Institutional Trading of OraSure Technologies
Wall Street Analyst Weigh In
OSUR has been the topic of several analyst reports. StockNews.com downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Saturday, August 17th. Evercore ISI upped their target price on OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research note on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, OraSure Technologies has an average rating of “Hold” and a consensus target price of $6.67.
View Our Latest Stock Analysis on OSUR
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Read More
- Five stocks we like better than OraSure Technologies
- Overbought Stocks Explained: Should You Trade Them?
- Should You Invest in Treasury Bills?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- Find and Profitably Trade Stocks at 52-Week Lows
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.